<DOC>
	<DOCNO>NCT01203735</DOCNO>
	<brief_summary>This non-randomized phase 2 study evaluate toxicity efficacy VA concurrent chemoradiotherapy ( CCRT ) contain weekly vinorelbine cisplatin patient locally advance inoperable non-small-cell lung cancer ( NSCLC ) .All patient plan three-dimensional conformal RT ( 3-DCRT ) . Concurrent weekly vinorelbine cisplatin oral valproic acid ( VA ) start first day RT . Follow conduct every 3 month completion study treatment . Toxicity assess use CTCAE , base clinical examination laboratory test study treatment follow visit . Response treatment evaluate use RECIST criterion . Overall progression free survival ( OS PFS ) estimate use Kaplan-Meier method .</brief_summary>
	<brief_title>Valproic Acid With Chemoradiotherapy Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Age &gt; 18 year . 2 . Newlydiagnosed , histologically cytologically confirm NSCLC . 3 . Inoperable stage IIIAB disease 4 . KPS &gt; 60 5 . FEV1 &gt; 1.2L 6 . No previous RT chest 7 . No serious comorbid condition 8 . No treatment biological response modifier cytotoxic agent within four week prior study entry 9 . No participation clinical trial use investigational drug device within four week prior study entry 10 . No serious complication malignant condition 11 . No previous concurrent malignancy sit except cone biopsied situ carcinoma uterine cervix adequately treat basal cell squamous cell carcinoma skin 12 . Adequate organ function evidence follow peripheral blood count serum chemistry study entry : Hemoglobin &gt; 9.0 Gm/dL WBC count &gt; 4.0x109/L Neutrophile count &gt; 1.5 cell x 109/L , Version 1 , May 12 , 2010 Platelet count &gt; 100 x 109/L , Creatinine &lt; 1.5 mg/dL Total bilirubin &lt; upper limit normal ( ULN ) AST/SGOT &lt; ULN Calcium &lt; ULN 13 . Ability sign inform consent 14 . Ability attend followup visit 1 . Operable disease 2 . Metastases contralateral mediastinal lymph node 3 . Distant metastases 4 . KPS &lt; 60 5 . FEV1 &lt; 1.2L 6 . Previous RT chest 7 . Treatment biological response modifier cytotoxic agent within four week prior study entry 8 . Participation clinical trial use investigational drug device within four week prior study entry 9 . Major surgical procedure within two week prior study entry 10 . Serious comorbid condition , inclusive limited myocardial infarction within previous six month , uncontrolled cardiac arrhythmia , uncontrolled angina pectoris , active infection include acute hepatitis 11 . Serious complication malignant condition 12 . Previous concurrent malignancy 13 . Inadequate organ function evidence follow peripheral blood count serum chemistry study entry : Hemoglobin &lt; 9.0 Gm/dL WBC count &lt; 4.0x109/L Neutrophile count &lt; 1.5 cell x 109/L , Platelet count &lt; 100 x 109/L , Creatinine &gt; 1.5 mg/dL Total bilirubin &gt; ULN ( upper limit normal ) AST/SGOT &gt; ULN Version 1 , May 12 , 2010 Calcium &gt; ULN 14 . Inability sign inform consent 15 . Psychological , familial , sociological geographical condition permit regular medical followup compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Non-small-cell lung cancer</keyword>
	<keyword>Valproic acid</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>